Table 3 Patient-reported outcomes

1MTP pain VAS (mm)

Control (ref.)

1.7

Gout

8.4

6.7

1.4

12.0

0.014

Asymptomatic hyperuricaemia

6.6

4.9

−0.1

10.0

0.055

General pain VAS (mm)

Control (ref.)

18.0

Gout

21.8

3.8

−9.9

17.5

0.581

Asymptomatic hyperuricaemia

29.2

11.3

−1.7

24.3

0.088

Patient global VAS (mm)

Control (ref.)

11.5

Gout

23.6

12.0

0.9

23.1

0.034

Asymptomatic hyperuricaemia

21.3

9.8

−0.8

20.3

0.068

HAQ-DI

Control (ref.)

0.11

Gout

0.44

0.33

0.13

0.54

0.002

Asymptomatic hyperuricaemia

0.32

0.21

0.02

0.41

0.033

LLTQ - daily

Control (ref.)

38.6

Gout

33.3

−5.3

−8.6

−2.0

0.002

Asymptomatic hyperuricaemia

35.0

−3.6

−6.8

−0.4

0.026

LLTQ – recreational

Control (ref.)

34.2

Gout

20.8

−13.4

−19.0

−7.9

<0.001

Asymptomatic hyperuricaemia

27.2

−7.0

−12.3

−1.8

0.010

MFPDI

Control (ref.)

1.826

Gout

13.3

11.5

7.7

15.3

<0.001

Asymptomatic hyperuricaemia

3.0

1.2

−2.4

4.8

0.511

Odds ratio

p

Lower

Upper

Presence of disabling foot pain

Control (ref.)

Gout

13.4

3.69

48.68

<0.001

Asymptomatic hyperuricaemia

4.2

1.36

12.8

0.013